Management of Uncontrolled Hypertension on Lisinopril-HCTZ

Rationale for Treatment Approach

The European Society of Cardiology recommends adding a calcium channel blocker to the current lisinopril-HCTZ regimen for patients with uncontrolled hypertension, as the combination of ACE inhibitor + thiazide diuretic + calcium channel blocker represents guideline-recommended triple therapy targeting three complementary mechanisms: renin-angiotensin system blockade, volume reduction, and vasodilation 1
The American Heart Association and European Society of Cardiology endorse the combination of RAS blocker + CCB + thiazide diuretic for uncontrolled hypertension, providing superior BP control and cardiovascular outcome benefits in patients with diabetes, chronic kidney disease, and heart failure 1

The European Society of Cardiology recommends replacing HCTZ with chlorthalidone 12.5-25 mg daily, which provides superior 24-hour BP control and greater overnight BP reduction compared to HCTZ 4
Adding spironolactone 25-50 mg daily as the preferred fourth-line agent for resistant hypertension can provide an average additional BP reduction of 25/12 mmHg when added to existing multidrug regimens 1

The European Society of Cardiology recommends a target BP of <140/90 mmHg minimum, ideally <130/80 mmHg for most patients, and reassessing within 2-4 weeks after any medication adjustment 1
Monitoring serum potassium and creatinine within 2-4 weeks of adding or increasing ACE inhibitor or diuretic doses is crucial to avoid hyperkalemia and renal dysfunction 3

The American Heart Association recommends sodium restriction to <2 g/day, weight loss if overweight, regular physical exercise, and alcohol limitation to provide an additional 10-20 mmHg BP reduction 2, 4, 5